The suit is part of an ongoing, two-year long antitrust investigation conducted by the U.S. Department of Justice.
Pharmaceuticals are all too often controlled and hoarded by mega corporations who charge exorbitant fees to obtain them.
Pharmaceutical company Mylan has made news recently by raising the price of a popular and important drug. Mylan acquired a product by the name of EpiPen in 2007. At the time, the price of the product was approximately $100 per unit. And, thanks to their government-granted monopoly, the price quickly shot up to $600 after Mylan’s acquisition.